CB-1158 (INCB001158)

About Calithera Biosciences

Calithera Biosciences was founded in 2010 with a mission to develop novel small-molecule drugs targeting critical metabolic pathways in cancer cells and the tumor microenvironment. Its strategy centered on two core platforms: arginase inhibition to modulate immune function and glutaminase inhibition to starve tumors. The company advanced multiple candidates into clinical trials and built a pipeline of ~30 programs, but ultimately discontinued development and wound down operations in 2023 after a strategic review of its clinical prospects.

Therapeutic Areas

Other Advanced/Metastatic Solid Tumors Drugs